Corporate strategies and tactics for more effective drug development.
March 24, 2009
By:
John Waslif, Jelena Markovic
Evidence-based medicine is fast becoming one of the key concepts in clinical and reimbursement practices in the developed world
|
February 1, 2009
By:
Joanna Breitstein
The world is suffering. But just over the horizon is a new access equation that could speed innovative vaccines to where they're needed most.
|
January 14, 2009
By:
George Koroneos, Online Content & News Editor
Sales reps aren't the only ones heading for the unemployment line - Pfizer is eliminating researcher positions as fewer drugs are making it to development. But could streamlining the crux of drug R&D cause more harm than good?
|
January 9, 2009
By:
Philip W. Fiscus
As global regulators set up rules for liability insurance for clinical trials, the playing field has grown complex for sponsors. This article reviews the key issues and offers a look at how European, Asian, and Latin American countries handle clinical trial insurance.
|
January 6, 2009
By:
Linda Meyerson, Tracy Harmon Blumenfeld
When it comes to working with clinical research sites, pharmaceutical companies should take a page out of the automakers' playbook
|
January 6, 2009
By:
Kristina Caggiano
The debate over gene sequence patents is leaving investors lost and confused. These strategies will help them find their way
|
December 12, 2008
By:
Gen Li
A new study of hundreds of thousands of clinical trial records reveals that the overall length of a trial is directly related to how long it takes to activate the study sites - and that most companies are wasting precious weeks and even months in activation. Here's how to improve your performance.
|
December 1, 2008
By:
Ron Feemster
We scrub industry's pipeline to find the drugs that everyone will be talking about in 2009 and beyond
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
